On April 24, 2021, proposed Regulations Amending the Patented Medicines (Notice of Compliance) Regulations were published (proposed PMNOC
amendments).
The proposed PMNOC amendments relate to the 2019 proposed Regulations Amending the Food and Drug Regulations (Improving Access to Generics) (proposed FDR amendments)(previously reported here), which would allow a generic manufacturer to file an abbreviated new drug submission for a different salt form of the medicinal ingredient in the
Canadian reference product. The proposed FDR amendments have not yet been finalized.
The objective of the proposed PMNOC amendments is to make patents with claims related to a different salt form of an approved medicinal ingredient eligible for inclusion on the Patent Register by extending the definition of “claim for the medicinal ingredient” to a claim for certain variations, such as a salt:
Current provision
claim for the medicinal ingredient
includes a claim in the patent for the medicinal ingredient, whether chemical or biological in nature, when prepared or produced by the methods or processes of manufacture particularly
described and claimed in the patent, or by their obvious chemical equivalents, and also includes a claim for different polymorphs of the medicinal ingredient, but does not include different chemical forms of the medicinal ingredient; (revendication de l’ingrédient médicinal)
Proposed amendment
claim for the medicinal ingredient
includes a claim in the patent for the medicinal ingredient, whether chemical or biological in nature, when prepared or produced by the methods or processes of manufacture particularly
described and claimed in the patent, or by their obvious chemical equivalents, and also includes a claim for different polymorphs of the medicinal ingredient and a claim for a variation of the medicinal ingredient that, when compared to the medicinal ingredient, is identical, excluding those appended portions, if any, that cause either the variation or the medicinal ingredient to be a salt, hydrate or solvate, but does not include other chemical forms of the medicinal ingredient; (revendication de l'ingrédient médicinal)
A transitional provision would allow the first person to submit or resubmit patents on a patent list within 30 days after the day the amendments come into force if (a) the patent was previously ineligible but would be eligible under the amended definition
and (b) the patent was issued in relation to a patent application with a filing date in Canada that precedes the filing date of the submission or supplement.
The proposed PMNOC amendments would come into force on the same day as the proposed FDR amendments, or if registered after, on the date of registration. Interested persons may submit comments until May 24, 2021.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Health Canada releases new guidance document on clinical evidence requirements for medical devices
On November 15, 2022, Health Canada released a new guidance document, “ Guidance on clinical evidence requirements for medical devices.” In it, Health Canada provides guidance on clinical evidence req...Read More -
Federal Court rejects pre-trial determination of a question of law about the nature of the section 8 but-for world
As previously reported, the Federal Court found Janssen’s Canadian Patent No. 2,661,422 (422 patent) – which relates to treatment of prostate cancer in humans by co-administration of abiraterone aceta...Read More -
Federal Court of Appeal restores Minister of Health’s decision to grant RUZURGI NOC despite FIRDAPSE data protection
The Federal Court found that subsection C.08.004.1(3) of the Food and Drug Regulations applied to prevent the Minister from issuing an NOC in view of the data protection granted to FIRDAPSE, a drug co...Read More